COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02608073
Recruitment Status : Completed
First Posted : November 18, 2015
Last Update Posted : March 2, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study will evaluate the efficacy, safety, tolerability, and effect on quality of life of oral capecitabine in combination with intravenous (IV) cisplatin in participants with metastatic nasopharyngeal cancer. Participants will receive up to 8 cycles of capecitabine treatment, and cisplatin will be administered on the first day of each cycle. The anticipated time on study treatment is up to 24 weeks, and the target sample size is 44 individuals.

Condition or disease Intervention/treatment Phase
Nasopharyngeal Cancer Drug: Capecitabine Drug: Cisplatin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center Phase II Trial of Capecitabine (Xeloda) in Combination With Cisplatin as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma
Study Start Date : November 2004
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Capecitabine + Cisplatin
Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
Drug: Capecitabine
Participants will receive oral capecitabine, 1000 mg/m^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
Other Name: Xeloda

Drug: Cisplatin
Participants will receive cisplatin, 100 mg/m^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: up to 28 days after the last intake of study treatment (up to approximately 5 years) ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Up to approximately 18 months ]
  2. Time to disease progression [ Time Frame: Up to approximately 18 months ]
  3. Duration of response [ Time Frame: Up to approximately 18 months ]
  4. Complete response rate [ Time Frame: Up to approximately 18 months ]
  5. Incidence of adverse events [ Time Frame: Up to approximately 7 months ]
  6. Quality of life according to Visual Analog Scale (VAS) score [ Time Frame: Up to approximately 6 months ]
  7. Treatment convenience/satisfaction according to VAS score [ Time Frame: Up to approximately 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults 18 to 75 years of age
  • Histologically confirmed, poorly differentiated or undifferentiated metastatic nasopharyngeal cancer with at least 1 measurable lesion which has not been irradiated
  • Ability to swallow and retain oral medication

Exclusion Criteria:

  • Previous cytotoxic chemotherapy except adjuvant, concurrent, or neoadjuvant treatment completed at least 6 months before enrollment
  • Clinically significant cardiac disease
  • History of other malignancy within the last 5 years except cured basal cell cancer of the skin or cured cancer in situ of the cervix
  • Radiotherapy within 4 weeks of treatment start or any prior radiotherapy performed to the indicator lesion(s) being measured in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02608073

Layout table for location information
Hong Kong
Hong Kong, Hong Kong, 852
Hong Kong, Hong Kong
Jogjakarta, Indonesia, 55284
Kuala Lumpur, Malaysia, 50603
Kueishan, Taiwan, 333
Taipei, Taiwan, 00112
Taipei, Taiwan, 106
Bangkok, Thailand, 10330
Bangkok, Thailand, 10400
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for investigator information
Study Chair: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche Identifier: NCT02608073    
Other Study ID Numbers: ML18123
First Posted: November 18, 2015    Key Record Dates
Last Update Posted: March 2, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Nasopharyngeal Neoplasms
Nasopharyngeal Carcinoma
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action